NCT05855083

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Pediatric Patients (28 Days to ≤ 18 Years of Age.) With High-Risk Hematopoietic Stem Cell Transplant Thrombotic Microangiopathy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Omeros Corporation · Industry
• Sex: All
• Age: 28 Days – 17 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).

Detailed description

This is a Phase 2, uncontrolled, single-dosing regimen study in pediatric patients from 28 days to less than 18 years of age with high risk HSCT-TMA. At least 4 patients will be required from each of 3 age cohorts: 28 days to \<2 years of age, 2 years to \<12 years of age, and 12 years to \<18 years of age. Treatment will be for 8 weeks and patients will be followed for up to 52 weeks.

Conditions

• Thrombotic Microangiopathies
• Hematopoietic Stem Cell Transplantation

Interventions

Type	Name	Description
DRUG	Biological: narsoplimab	Treatment with narsoplimab 4 mg/kg will be administered

Timeline

• Start date: 2023-05-01
• Primary completion: 2025-12-01
• Completion: 2025-12-01
• First posted: 2023-05-11
• Last updated: 2025-03-25

Locations

16 sites across 5 countries: United States, Germany, Israel, Netherlands, Spain

Regulatory

• FDA-regulated drug study